Evidence map›Paper›PMID 42593204›Full record

ArticleTranslational vision science & technology2026

Visual Field Progression Rate and Laminar Depth and Curvature in the African Descent and Glaucoma Evaluation Study (ADAGES).

Karla Murillo, Anuwat Jiravarnsirikul, Evan Walker, Massimo A Fazio, Stuart Gardiner, Robert N Weinreb, Jeffrey M Liebmann, Linda M Zangwill, Christopher A Girkin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational vision science & technology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Karla MurilloProgram in Medical Education - Leadership & Advocacy (PRIME-LA), David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Anuwat JiravarnsirikulHamilton Glaucoma Center, Shiley Eye Institute, Viterbi Family Department of Ophthalmology, University of California, San Diego, La Jolla, CA, USA.
Evan WalkerHamilton Glaucoma Center, Shiley Eye Institute, Viterbi Family Department of Ophthalmology, University of California, San Diego, La Jolla, CA, USA.
Massimo A FazioDepartment of Ophthalmology, School of Medicine, The University of Alabama at Birmingham, Birmingham, AL, USA.
Stuart GardinerDiscoveries in Sight, Devers Eye Institute, Legacy Health, Portland, OR, USA.
Robert N WeinrebHamilton Glaucoma Center, Shiley Eye Institute, Viterbi Family Department of Ophthalmology, University of California, San Diego, La Jolla, CA, USA.
Jeffrey M LiebmannBernard and Shirlee Brown Glaucoma Research Laboratory, Edward S. Harkness Eye Institute, Columbia,University Medical Center, New York, NY, USA.
Linda M ZangwillHamilton Glaucoma Center, Shiley Eye Institute, Viterbi Family Department of Ophthalmology, University of California, San Diego, La Jolla, CA, USA.
Christopher A GirkinHamilton Glaucoma Center, Shiley Eye Institute, Viterbi Family Department of Ophthalmology, University of California, San Diego, La Jolla, CA, USA.

Funding

Vision BiostatisticsP30EY022589 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LINDA M ZANGWILL · 2012 to 2026
$10.3M
Diagnostic Innovations in Glaucoma Study (DIGS): High Myopia and Advanced DiseaseR01EY027510 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LINDA M ZANGWILL · 2017 to 2026
$5.3M
African Descent and Glaucoma Evaluation (ADAGES) IV: Alterations of the lamina cribrosa in progressionR01EY026574 · NEI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI FAZIO, MASSIMO ANTONIO, GIRKIN, CHRISTOPHER ANTHONY · 2017 to 2020
$2.6M
Short-Term Research training In Vision and Eye health (STRIVE)T35EY033704 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Jolene Rudell, LINDA M ZANGWILL · 2022 to 2026
$144k
NEI NIH HHS P30 EY022589NEI NIH HHS R01 EY026574NEI NIH HHS R01 EY027510NEI NIH HHS T35 EY033704
6 · The paper itself

Abstract

Purpose: To evaluate whether lamina cribrosa (LC) depth and curvature predict visual field (VF) progression in primary open-angle glaucoma (POAG) patients. Methods: Anterior laminar cribrosa surface depth (ALCSD) and LC curvature index (LCCI) were defined by spectral domain optic coherence tomographic (SDOCT) images. All scans were processed using a deep learning software to perform layer segmentation. Linear mixed-effects models were used to test associations between VF progression rate, ALCSD, and other demographic and clinical characteristics and known risk factors for progressive POAG. Results: A total of 584 eyes from 359 POAG patients were analyzed, comprising 167 African Descent (AD) eyes (292 eyes) and 192 European Descent (ED) eyes (292 eyes). There was a statistically significant relationship between faster VF progression rates, and a deeper ALCSD (-0.02 dB/year/50  µm, P < 0.001) and LCCI (-0.01 dB/year/unit, P < 0.001). There was also increasing progression seen in both models with increasing age (-0.025 dB/year/10 years, P < 0.007), intraocular pressure (IOP) (-0.011 dB/year per 2 mm Hg, P = 0.021), and disease severity (0.017 dB/year per dB, P < 0.001). The rate of progression was faster in the ED (used as the reference group) cohort (-0.056 dB/year, P = 0.006) following propensity matching for disease severity and age. Conclusions: In our cohort, there was a statistically significant association between VF rate and ALCSD and curvature (LCCI). A 50  µm deeper LC at baseline had a similar effect on VF progression as being 10 years of age or older. Translational Relevance: LC depth and curvature may serve as structural biomarkers to identify patients with glaucoma at a higher risk of progression.

Indexed as

Glaucoma, Open-AngleOptic DiskVisual FieldsAgedBlack PeopleDisease ProgressionFemaleHumansIntraocular PressureMaleMiddle AgedRisk FactorsTomography, Optical CoherenceWhite People

Identifiers

PMID42593204
PMCPMC13489204

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.